Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data

Moritz Gerstung, PhD, Elli Papaemmanuil, PhD, Inigo Martincorena, PhD, Lars Bullinger, MD, Verena I. Gaidzik, MD, Peter Paschka, MD, Michael Heuser, MD, Felicitas Thol, MD, Niccolo Bolli, MD PhD, Peter Ganly, BMBCh, PhD, Arnold Ganser, MD, Ultan McDermott, MD PhD, Michael R Stratton, MD PhD, Konstanze Döhner, MD, Hartmut Döhner, Prof. Dr., Richard F. Schlenk, MD, Peter J Campbell, MD PhD

Blood (2015) 126 (23): 85.

https://doi.org/10.1182/blood.V126.23.85.85

Published: 2015

Journal Articles

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Blood (2013) 122 (22): 3616–3627.

https://doi.org/10.1182/blood-2013-08-518886

Published: 2013

Includes: Supplemental data

Journal Articles

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

Elli Papaemmanuil, PhD, Moritz Gerstung, PhD, Luca Malcovati, MD, Sudhir Tauro, PhD, Gunes Gundem, PhD, Peter Van Loo, PhD, Andrea Pellagatti, PhD, Michael J Groves, PhD, Nick C.P. Cross, PhD, Carlo Gambacorti-Passerini, MD, Anthony R Green, MD, Jacqueline Boultwood, PhD, Paresh Vyas, MD, Eva Hellstrom-Lindberg, MD, David Bowen, MD, Mario Cazzola, MD, Michael R Stratton, MD, PhD, Peter Campbell, MD Phd

Blood (2012) 120 (21): LBA-5.

https://doi.org/10.1182/blood.V120.21.LBA-5.LBA-5

Published: 2012

Journal Articles

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Blood (2011) 118 (24): 6239–6246.

https://doi.org/10.1182/blood-2011-09-377275

Published: 2011

Includes: Supplemental data

Journal Articles

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

Blood (2011) 118 (21): 3.

https://doi.org/10.1182/blood.V118.21.3.3

Published: 2011

Journal Articles

The V617F JAK2 Mutation Is Uncommon in Cancers and Mutations in STAT5A, STAT5B and the JAK Family Genes Do Not Account for V617F Negative Myeloproliferative Disorders.

Joanna E. Baxter, Linda M. Scott, Peter J. Campbell, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R. Stratton, Andrew P. Futreal, Anthony R. Green

Blood (2005) 106 (11): 2598.

https://doi.org/10.1182/blood.V106.11.2598.2598

Published: 2005

Journal Articles

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

Linda M. Scott, Peter J. Campbell, E. Joanna Baxter, Tony Todd, Philip Stephens, Sarah Edkins, Richard Wooster, Michael R. Stratton, P. Andrew Futreal, Anthony R. Green

Blood (2005) 106 (8): 2920–2921.

https://doi.org/10.1182/blood-2005-05-2087

Published: 2005

NARROW

Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data

Clinical and biological implications of driver mutations in myelodysplastic syndromes

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

The V617F JAK2 Mutation Is Uncommon in Cancers and Mutations in STAT5A, STAT5B and the JAK Family Genes Do Not Account for V617F Negative Myeloproliferative Disorders.

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

Email alerts

ASH Publications

American Society of Hematology

Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data

Clinical and biological implications of driver mutations in myelodysplastic syndromes

High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Somatic Mutation of SF3B1 , a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts

The V617F JAK2 Mutation Is Uncommon in Cancers and Mutations in STAT5A, STAT5B and the JAK Family Genes Do Not Account for V617F Negative Myeloproliferative Disorders.

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only